FAP and neoplasm: To enhance tumor retention, Moon et al. (11) and Martin et al. (12) developed bivalent FAP inhibitors such as DOTAGA.(SA.FAPi)2, which exhibited prolonged tumor residence time and increased uptake compared to the monomeric DOTA.SA.FAPi (effective half-life, 86.6 h vs. 14 h) (13).